Literature DB >> 18421233

Uveitis secondary to bacterial products.

James T Rosenbaum1, Holly L Rosenzweig, Justine R Smith, Tammy M Martin, Stephen R Planck.   

Abstract

Bacteria are suspected contributors to several forms of immune-mediated, noninfectious forms of uveitis including that associated with ankylosing spondylitis, sarcoidosis, Behçet's disease and inflammatory bowel disease. Endotoxin (lipopolysaccharide)-induced uveitis has been a widely used model for more than 2 decades. Both rats and mice develop a transient, bilateral anterior uveitis after a systemic injection of endotoxin. Inflammation posterior to the lens is generally milder than anterior segment inflammation. The uveitis is severer if the lipopolysaccharides are injected intraocularly. The model has been invaluable in helping to identify mediators induced in the inflamed eye and in testing pharmacologic approaches to reduce eye inflammation. Muramyl dipeptide is another bacterial cell component that can induce uveitis in laboratory animals. Muramyl dipeptide is especially intriguing as a cause of uveitis because it activates the intracellular protein, Nod2, and mutations in the NOD2 gene are the cause of the autosomal dominant form of uveitis that is characteristic of Blau syndrome. Since a mutation in a gene that codes for a protein which senses a bacterial product consistently results in uveitis, it is critical to understand more fully the mechanisms by which bacterial products cause uveitis in laboratory animals. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18421233     DOI: 10.1159/000119870

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  14 in total

Review 1.  Emerging role of antioxidants in the protection of uveitis complications.

Authors:  U C S Yadav; N M Kalariya; K V Ramana
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice.

Authors:  Yiguo Qiu; Pollob Kumar Shil; Ping Zhu; Hongxia Yang; Amrisha Verma; Bo Lei; Qiuhong Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

3.  Plasma metabonomics study of the patients with acute anterior uveitis based on ultra-performance liquid chromatography-mass spectrometry.

Authors:  Junguo Guo; Tingqin Yan; Hongsheng Bi; Xiaofeng Xie; Xingrong Wang; Dadong Guo; Haiqiang Jiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-08       Impact factor: 3.117

4.  NOD1 expression in the eye and functional contribution to IL-1beta-dependent ocular inflammation in mice.

Authors:  Holly L Rosenzweig; Kellen T Galster; Stephen R Planck; James T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-13       Impact factor: 4.799

5.  Bowman lecture on the role of inflammation in degenerative disease of the eye.

Authors:  J V Forrester
Journal:  Eye (Lond)       Date:  2013-01-04       Impact factor: 3.775

6.  Investigation of the peptidoglycan sensing molecule, PGLYRP-2, in murine inflammatory uveitis.

Authors:  Jenna S Clowers; Jordan J Allensworth; Ellen J Lee; Holly L Rosenzweig
Journal:  Br J Ophthalmol       Date:  2013-01-29       Impact factor: 4.638

7.  Understanding autoimmunity in the eye: from animal models to novel therapies.

Authors:  Rachel R Caspi
Journal:  Discov Med       Date:  2014-03       Impact factor: 2.970

Review 8.  Role of inflammation in endophthalmitis.

Authors:  J L Vallejo-Garcia; M Asencio-Duran; N Pastora-Salvador; P Vinciguerra; M R Romano
Journal:  Mediators Inflamm       Date:  2012-09-02       Impact factor: 4.711

9.  Comparative analysis of induced vs. spontaneous models of autoimmune uveitis targeting the interphotoreceptor retinoid binding protein.

Authors:  Jun Chen; Haohua Qian; Reiko Horai; Chi-Chao Chan; Yishay Falick; Rachel R Caspi
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

10.  Retinal astrocytes pretreated with NOD2 and TLR2 ligands activate uveitogenic T cells.

Authors:  Guomin Jiang; Deming Sun; Henry J Kaplan; Hui Shao
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.